Compare Twist Bioscience Corp (TWST) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Vanguard Total World Stock Index Fund ETF — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Vanguard Total World Stock Index Fund ETF trades at $160.99. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.
| TWST | VT | |
|---|---|---|
Market Cap | $8.42B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $153.10 | $162.39 |
52-Week Low | $24.16 | $134.19 |
Enterprise Value | $8.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
VT trades at $160.92, down 0.5% on the day, with a bullish technical signal driven by moving averages and neutral oscillators. The ETF offers broad global equity diversification with over 10,000 stocks and a low 0.06% expense ratio. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced holdings.
The outlook remains favorable for long-term investors seeking global exposure, supported by cost efficiency and diversification benefits. Risks include trade policy uncertainty and market volatility, but VT's structure mitigates single-country or sector risks. Analyst sentiment is generally positive, emphasizing its role as a core holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
